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IMPORTANCE Current treatments for long-term prophylaxis in hereditary angioedema
have limitations.
OBJECTIVE To assess the efficacy of lanadelumab, a fully humanmonoclonal antibody that
selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks.
DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, double-blind, parallel-group,
placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United
States. Patients were randomized betweenMarch 3, 2016, and September 9, 2016; last day
of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients
assigned to lanadelumabwere further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12
years or older with hereditary angioedema type I or II underwent a 4-week run-in period and
those with 1 or more hereditary angioedema attacks during run-in were randomized.
INTERVENTIONS Twenty-six-week treatment with subcutaneous lanadelumab 150mg every 4
weeks (n = 28), 300mg every 4 weeks (n = 29), 300mg every 2 weeks (n = 27), or placebo
(n = 41). All patients received injections every 2 weeks, with those in the every-4-week group
receiving placebo in between active treatments.
MAIN OUTCOME ANDMEASURES Primary efficacy end point was the number of
investigator-confirmed attacks of hereditary angioedema over the treatment period.
RESULTS Among 125patients randomized (meanage, 40.7 years [SD, 14.7 years]; 88 females
[70.4%]; 113white [90.4%]), 113 (90.4%) completed the study.During the run-inperiod, the
meannumberof hereditary angioedemaattackspermonth in theplacebogroupwas4.0; for the
lanadelumabgroups, 3.2 for theevery-4-week 150-mggroup; 3.7 for theevery-4-week300-mg
group; and3.5 for theevery-2-week300-mggroup.During the treatmentperiod, themeannum-
ber of attackspermonth for theplacebogroupwas 1.97; for the lanadelumabgroups,0.48 for the
every-4-week 150-mggroup;0.53 for theevery-4-week300-mggroup; and0.26 for theevery-2-
week300-mggroup. Comparedwithplacebo, themeandifferences in the attack ratepermonth
were−1.49 (95%CI, −1.90 to−1.08;P < .001); −1.44 (95%CI, −1.84 to−1.04;P < .001); and−1.71
(95%CI, −2.09 to−1.33;P < .001). Themost commonlyoccurring adverse eventswith greater
frequency in the lanadelumab treatment groupswere injection site reactions (34.1%placebo,
52.4% lanadelumab) anddizziness (0%placebo,6.0% lanadelumab).
CONCLUSIONSANDRELEVANCE AmongpatientswithhereditaryangioedematypeIor II, treatment
withsubcutaneous lanadelumabfor26weekssignificantly reducedtheattack ratecomparedwith
placebo. These findings support the use of lanadelumab as a prophylactic therapy for hereditary
angioedema. Further research is needed to determine long-term safety and efficacy.
TRIAL REGISTRATION EudraCT Identifier: 2015-003943-20; ClinicalTrials.gov Identifier:
NCT02586805
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H ereditary angioedema with C1 inhibitor deficiency isa rare autosomal dominant disorder due to C1 inhibi-tordeficiency (type I)ordysfunction (type II) that leads
to dysregulated plasma kallikrein activity, excess bradykinin
production, andunpredictablepotentially life-threatening re-
current angioedema attacks.1,2 Patients with hereditary an-
gioedemaare often limited in their ability to performdaily ac-
tivities at work, school, or home; experience symptoms of
anxiety and depression; face a risk of asphyxiation due to la-
ryngealattacks; andreportpoorhealth-relatedqualityof life.3-5
Currently availableprophylactic therapeutic optionshave
important limitations.Oral androgensmayhavesubstantial ad-
verse effects that may require close monitoring.6,7 Intrave-
nousC1 inhibitor treatment is limited by venous access issues
and complications of indwelling ports. Subcutaneous C1 in-
hibitor treatment with higher doses may require larger vol-
umes than typical for subcutaneous injections.8 Both intra-
venous and subcutaneous administration require frequent
administration every 3 to 4 days.8-10 Furthermore, antifibri-
nolyticshavedemonstratedminimal efficacy.11 Thus, there re-
mains an unmet need in the management of hereditary
angioedema for an effective,well-tolerated, conveniently ad-
ministered, long-acting prophylactic therapy.5
Lanadelumab is a fully human monoclonal antibody that
bindsand inhibits activeplasmakallikrein, therebypreventing
the cleavage of high-molecular-weight kininogen and the gen-
eration of bradykinin.12,13 Lanadelumab does not inhibit the
tissuekallikrein-kininsystem,whichmaintainsbradykinin lev-
els for importantphysiological andcardiovascular functions.13
Inaphase 1bstudy, lanadelumabwaswell toleratedandsignifi-
cantly inhibitedproteolysisofhigh-molecular-weightkininogen
inadose-dependentmannerandwasassociatedwithreductions
in hereditary angioedema attacks.12,14,15 The objective of the
HereditaryAngioedemaLong-termProphylaxis (HELP) clinical
trialwastodeterminetheefficacyoflanadelumabcomparedwith
placebo for preventing hereditary angioedema attacks.
Methods
Trial Design andOversight
The study was conducted in accordance with International
ConferenceonHarmonisationofGoodClinical Practice guide-
lines and theprinciplesof theDeclarationofHelsinki,16 aswell
asother applicable local ethical and legal requirements.All pa-
tients or caregivers providedwritten informed consent (or as-
sent frompatients<18years) at screening.An independentdata
and safetymonitoringboardprovidedoversight, including re-
view and assessment of unblinded study data (Trial Protocol
in Supplement 1).
This was a randomized, double-blind, parallel-group,
placebo-controlled trial at 41 sites in Canada, Europe, Jordan,
and the United States that evaluated the efficacy, adverse
events, andother safetyparametersof subcutaneously admin-
istered lanadelumab in preventing hereditary angioedema at-
tacks. Theoriginal protocol and the statistical analysis plan for
thisstudyareavailable(Supplement1).Attheendofthe26-week
treatment period, patients could enter either an open-label
extensionstudy (HELPStudyExtension,NCT02741596)17 or an
8-week safety follow-up (eFigure 1 in Supplement 2).
Patient Enrollment
Patients were 12 years or older at screening with a confirmed
diagnosis of hereditary angioedema type I or II (See eMethods
1 inSupplement2for full inclusionandexclusioncriteria.)Race/
ethnicitydatawereself-reportedbypatientsusing fixedcatego-
ries and collected by qualified staff at each site in accordance
withUSFoodandDrugAdministrationregulations.Patientsun-
derwent a4-week run-inperiod (precededbya≥2-weekwash-
out of any long-termprophylactic therapy if applicable) to de-
termine their baseline attack rate. Patients with 1 or more
investigator-confirmedattackper4weekswereeligible for en-
rollment (eMethods 2 in Supplement 2). The study was pow-
ered to compareeffectsof lanadelumabvsplacebobutwasnot
designed or powered to compare the effects of the 3 lanadel-
umab groups.
Study Treatment Protocol
Patients, caregivers of patients younger than 18 years, investi-
gators, site personnel, and the sponsor were blinded to study
treatment until the studywas complete. Eligible patientswere
randomized 2:1 to receive subcutaneously injected lanadel-
umab or placebo. Patients randomized to receive lanadel-
umab were assigned in a 1:1:1 ratio to 1 of 3 lanadelumab dose
regimens: 150 mg every 4 weeks, 300 mg every 4 weeks, or
300 mg every 2 weeks (Figure 1). All patients received injec-
tions every2weeks,with those in the every-4-weekgroups re-
ceivingplacebo inbetweenactive treatments.Patientswereen-
rolled and assigned to interventions using an interactive web-
based randomization system (Rho Inc) by blinded study staff
in theorderofenrollment.Randomizationwasstratifiedbynor-
malizednumberofattacksduringtherun-inperiod:1 to lessthan
2, 2 to less than 3, or 3 or more attacks within 4 weeks using a
within-stratum block size of 9. Patients who experienced 3 or
more investigator-confirmed attacks before the end of the 4
weeksmay have exited the run-in period early and proceeded
to enrollment and randomization. Patients without 1 or more
investigator-confirmedattackafter4weeksof run-inmayhave
extended their run-in for another 4 weeks, during which time
they needed to have 2 ormore investigator-confirmed attacks
toproceed toenrollmentand randomization.Attack rateswere
normalized to the number of attacks over 4 weeks (28 days).
Key Points
Question Is lanadelumab, a monoclonal antibody that inhibits
plasma kallikrein, effective in preventing hereditary
angioedema attacks?
Findings In this randomized clinical trial involving 125 patients
with hereditary angioedema type I or II, treatment with
lanadelumab for 26 weeks significantly reduced themean attack
rate (0.26-0.53 attacks/month) compared with placebo (1.97
attacks/month).
Meaning These findings support the use of lanadelumab for the
prevention of hereditary angioedema attacks.
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Because patients may have had their run-in period shortened
or extended, noninteger valueswerepossible. Eachpatient re-
ceived 13 doses of blinded study drug over the 26-week treat-
ment period (days 0-182). Lanadelumab was provided as
a 150-mg/mLsolution, formulatedasdescribedpreviously.14,15
To maintain the blind, all patients received 2 injections of the
studydrugadministered in the sameupper arm(seeeMethods
3 in Supplement 2).
Treatment of attacks followed the site investigator’s stan-
dardofcare,whichcould include intravenousC1 inhibitor, icati-
bant, or ecallantide. Long-term prophylaxis, angiotensin-
convertingenzyme inhibitors, exogenousestrogens, andother
investigational products were prohibited during the study.
Short-termprophylaxis for procedureswaspermitted ifmedi-
cally indicated.
OutcomeMeasures
All hereditary angioedema attacks analyzed for the primary,
secondary, and exploratory endpointswere investigator con-
firmed. Patients notified and reporteddetails to the study site
within72hoursof theonsetof ahereditaryangioedemaattack.
Theprimaryefficacyendpointwas thenumberof attacksdur-
ing the 26-week treatment period. Secondary end points in-
cluded the number of attacks requiring acute treatment dur-
ing the 26-week treatment period, number of moderate or
severe18 attacks (eMethods 4 in Supplement 2) during the
26-week treatment period, and number of attacks from days
14 through182.Additionalprespecifiedexploratoryendpoints
included the percentage of patients who were attack-free,
number of attack-free days, responders, and number of high-
morbidity attacks. An attack-free day was defined as a calen-
dardaywithno investigator-confirmedattack.Anypatientwho
achieved at least a prespecified reduction in attack rate rela-
tive to baselinewasdefined as a responder; responder thresh-
olds included reductions of 50% or more, 70% or more, and
90%ormore.Ahigh-morbidityattackwasdefinedasanyattack
thatwas severe, laryngeal,hemodynamically significant, or re-
sulted inhospitalization.Maximumattackseverity (attack free,
mild,moderate,or severe), attack location,attackduration,and
on-demand medication use to treat attacks also were evalu-
ated. Prespecified subgroup analyses were conducted based
onhereditaryangioedemadiseaseorpatient characteristics in-
cluding long-term prophylaxis use before study entry, run-in
period attack rate, sex, and bodymass index. The attack rates
andpercentageofpatientsattack-freeduringa 16-weeksteady-
state period (days 70-182, based on anobserved lanadelumab
half-life of 14 days14)were compared across treatment groups
in a post hoc analysis. Health–related quality of life was as-
sessed using theAngioedemaQuality of Life Questionnaire, a
validated, self-administered, angioedema-specific quality of
Figure 1. Flowchart of Study Enrollment in a Trial of Lanadelumab for Hereditary Angioedema
159 Patients with hereditary angioedema
were assessed for eligibility
33 Excluded
24 Did not meet the inclusion criteria
5 Refused participation
4 Did not have the minimum number
of angioedema attacks during the
run-in period
126 Randomized
33 Entered the open-label
extension study
25 Entered the open-label
extension study
26 Entered the open-label
extension study
41 Randomized to receive placebo
41 Received placebo as
randomized
27 Randomized to receive 300 mg
of lanadelumab every 2 weeks
27 Received treatment as
randomized
29 Randomized to receive 150 mg
of lanadelumab every 4 weeks
28 Received treatment as
randomized
1 Did not receive treatment
as randomizeda
29 Randomized to receive 300 mg
of lanadelumab every 4 weeks
29 Received treatment as
randomized
25 Entered the open-label
extension study
41 Included in the primary analysis
41 Included in the safety analysis
27 Included in the primary analysis
27 Included in the safety analysis
28 Included in the primary analysis
28 Included in the safety analysis
29 Included in the primary analysis
29 Included in the safety analysis
6 Discontinued the study
3 Withdrew
2 Adverse event
1 Withdrawn by physician
2 Discontinued the study
(withdrew)
3 Discontinued the study
1 Withdrew
1 Adverse event
1 Lost to follow-up
1 Discontinued the study
(withdrew)
All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
a One patient was determined to be a screen failure after randomization to the
group that received 150mg of lanadelumab every 4 weeks. This patient was
not treated and was withdrawn from the study. This patient was counted in
the randomized population but was excluded from both the intent-to-treat
and safety populations.
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life instrument. Scores range from0 to 100with lower scores
indicating lower impairment (ie, higher health–related qual-
ity of life); theminimal clinically important difference for the
total score is 6.19,20
Adverse Events and Antidrug Antibodies
Adverse events following repeated subcutaneous lanadel-
umabadministrationswereanalyzed.Adverseeventswerecap-
tured over the entire treatment period (eMethods 4 in
Supplement 2). Although attacks also were captured as ad-
verse events, they are summarized only in the efficacy analy-
sis. The presence of antidrug antibodies was assessed by pre-
viouslydescribedmethods,14andpositivesampleswerefurther
analyzed for the presence of neutralizing antibodies.14
Statistical Analysis
Upto 120patientswereplanned forenrollment toprovide 108
patients who completed the study. A sample size of 24 pa-
tients for each active treatment group (72 patients total) and
36patients in theplacebo groupprovided95%ormorepower
(1-sided α = .025; active treatment group to placebo ratio set
at 1:1.5; 10%missing data) to detect a treatment effect of 60%
or more reduction in hereditary angioedema attacks com-
pared with placebo, assuming a placebo attack rate of 0.3 per
week. This sample sizewas based on simulations using a gen-
eralized linear model for count data assuming a Poisson dis-
tribution with Pearson χ2 scaling of SEs to account for poten-
tial overdispersion. A reduction of 60% or more is a good
estimate of the treatment effect that might be seen based on
previousprophylactic studies conducted inhereditary angio-
edema; a 12-weekstudywithC1-inhibitor treatment showeda
reductionofapproximately50%inthenumberofattackscom-
pared with placebo.9 This study was powered to compare ef-
fects of lanadelumabvsplacebobutwasneither designednor
powered to compare the effects of the 3 lanadelumab groups
All efficacy analyses were conducted using the intent-to-
treat population, defined as all randomized patients exposed
to study treatment; analyseswereperformedaccording topa-
tients’ randomizedtreatmentassignment.Adverseeventanaly-
ses were conducted using the safety population, which in-
cluded all patients who received 1 or more dose of study
treatment; analyses were performed according to the actual
treatment received.
Statistical analyseswere conductedusing SASversion9.4
(SAS Institute Inc). eMethods5 inSupplement2provides ade-
taileddescriptionof statisticalmethods. Theprimary and sec-
ondaryefficacyendpoints foreachactive treatmentgroupwere
compared with the placebo group using a Poisson regression
model including a covariate for the normalized run-in period
attack rate and accounting for potential overdispersion, with
the overall type I error controlled at .05. A post hoc analysis
that included region (United States vs non-United States) as a
categorical covariatewas also conducted.Toadjust for thepo-
tential of an inflated overall type I error rate due to multiple
comparisons, the primary end point and rank-ordered sec-
ondary endpointswere tested in a fixed sequence for each la-
nadelumab treatment group vs the placebo group compari-
sonata 1.67%significance level (α/3;2-sided).All availabledata
were included in the primary and secondary efficacy analy-
ses. The logarithm of the number of days a patient was ob-
served during the treatment period was included as an offset
variable in the generalized linear model to adjust for differ-
ences in follow-up time. A tipping-point analysis was con-
ducted tomeasure the potential effect of missing data on the
reliability of the primary efficacy analysis. The observed por-
tion of the treatment period was used for the analysis of bi-
naryoutcomes.Exploratorybinaryandcontinuousendpoints
for each lanadelumab treatment group were compared with
the placebo groupwithout adjustment for multiplicity, using
Fisher exact test and t test, respectively.
Results
A total of 125 patientswere randomized and treated (placebo,
n = 41; lanadelumab, n = 84), and 113 (90.4%) completed the
study; themajority (109 of 113; 96.5%) entered the open-label
extension17 (Figure 1). Of the 12 patients who did not com-
plete the study, 6 received placebo and 6 received lanadel-
umab. eTable 2 inSupplement2details treatmentduration for
each patient who discontinued.
Patient Characteristics
The mean (SD) age among all patients was 40.7 years (14.7
years), 90.4% were white, and 70.4% were female (Table 1).
More than half of the patients in both the placebo and
lanadelumab groups (58.5% and 54.8%, respectively) re-
ported treatmentwith long-termprophylaxis in the 3months
before screening. Patients reported a mean of 3.7 attacks per
monthduring the run-in period.A total of 65patients (52.0%)
reported3ormoreattackspermonthduring the run-inperiod.
On average, 99.4%of blinded studydrugdoseswere received
per protocol.
Efficacy
Primary End Point
During the run-inperiod, themeanattack rate ranged from3.2
to 4.0 attacks permonth across the4 treatment groups. All la-
nadelumab treatment regimensweremore effective thanpla-
cebo for the primary end point. Themodel-basedmeannum-
berofattackspermonth fromdays0through182was 1.97 (95%
CI, 1.64-2.36) in the placebo group compared with 0.48 (95%
CI,0.31-0.73) in the 150-mgevery-4-weekgroup,0.53 (95%CI,
0.36-0.77) in the 300-mgevery-4-week group, and0.26 (95%
CI,0.14-0.46) in the300-mgevery-2-weekgroup (Figure2, A).
There were statistically significant reductions in attack rates
permonth; themeandifference in the lanadelumabgroups vs
the placebo group was −1.49 (95% CI, −1.90 to −1.08) in the
150-mg every-4-week group, −1.44 (95%CI, −1.84 to −1.04) in
the 300-mg every-4-week group, and −1.71 (95% CI, −2.09 to
−1.33) in the 300-mg every-2-week group (adjusted P < .001
for all comparisons). The mean rate ratio relative to placebo
was 0.24 (95% CI, 0.15 to 0.39) for the 150-mg every-4-week
group, 0.27 (95% CI, 0.18 to 0.41) for the 300-mg every-4-
week group, and 0.13 (95% CI, 0.07 to 0.24) for the 300-mg
every-2-week group (adjusted P < .001 for all comparisons).
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Themean attack rate over the treatment periodbymonth and
by treatment group is shown in eFigure 2 in Supplement 2.
Secondary End Points
The rate ratio for each lanadelumab group relative to placebo
showed a statistically significant reduction in attack rates for
all rank-orderedsecondaryefficacyanalyses (adjustedP < .001
for all comparisons). For attacks requiringacute treatment, the
mean per month difference in lanadelumab vs placebo was
−1.32 (95% CI, −1.69 to −0.95) for the 150-mg every-4-week
group, −1.21 (95%CI, −1.58 to −0.85) for the 300-mg every-4-
week group, and−1.43 (95%CI, −1.78 to −1.07) for the 300-mg
every-2-weekgroup.Formoderateor severe attacks, themean
difference vs placebo was −0.86 (95% CI, −1.18 to −0.53) for
the150-mgevery-4-weekgroup,−0.89 (95%CI,−1.20to−0.58)
for the 300-mg every-4-week group, and −1.01 (95%CI, −1.32
to−0.71) for the 300-mgevery-2-weekgroup.For attacks from
days 14 through 182, themeandifferencevsplacebowas−1.54
(95% CI, −1.96 to −1.12) for the 150-mg every-4-week group,
−1.50 (95% CI, −1.91 to −1.09) for the 300-mg every-4-week
Table 1. Baseline Characteristicsa
Characteristics
No. (%) of Patients
Lanadelumab
Placebo (n = 41)
Every 4 Weeks
300 mg Every
2 Weeks (n = 27)150 mg (n = 28) 300 mg (n = 29)
Age, mean (SD), y 43.4 (14.9) 39.5 (12.8) 40.3 (13.3) 40.1 (16.8)
<18 1 (3.6) 3 (10.3) 2 (7.4) 4 (9.8)
18 to <65 24 (85.7) 26 (89.7) 25 (92.6) 35 (85.4)
≥65 3 (10.7) 0 0 2 (4.9)
Females 20 (71.4) 19 (65.5) 15 (55.6) 34 (82.9)
Males 8 (28.6) 10 (34.5) 12 (44.4) 7 (17.1)
Raceb
White 25 (89.3) 23 (79.3) 26 (96.3) 39 (95.1)
Black 1 (3.6) 6 (20.7) 1 (3.7) 2 (4.9)
Asian 2 (7.1) 0 0 0
BMI, mean (SD)c 26.9 (4.7) 28.1 (5.1) 31.0 (7.8) 27.5 (7.7)
Hereditary angioedema type
Type I 25 (89.3) 27 (93.1) 23 (85.2) 38 (92.7)
Type II 3 (10.7) 2 (6.9) 4 (14.8) 3 (7.3)
Age at symptom onset, mean (SD), y 12.0 (8.8) 14.6 (11.2) 15.0 (8.7) 11.2 (8.2)
History of laryngeal attacks 17 (60.7) 17 (58.6) 20 (74.1) 27 (65.9)
No. of attacks in 12 mo before screening, median (IQR) 34 (12-55) 24 (12-50) 20 (8-36) 30 (17-59)
Use of long-term prophylaxis in 3 mo before screening
Plasma-derived C1 inhibitord 9 (32.1) 18 (62.1) 11 (40.7) 22 (53.7)
Oral therapye 2 (7.1) 1 (3.4) 0 1 (2.4)
Combination therapyf 1 (3.6) 1 (3.4) 3 (11.1) 1 (2.4)
No prophylaxis 16 (57.1) 9 (31.0) 13 (48.1) 17 (41.5)
Run-in hereditary angioedema attack rate, mean (SD),
attacks per mog
3.2 (1.8) 3.7 (2.5) 3.5 (2.3) 4.0 (3.3)
Normalized run-in attack rate category, attacks per moh,i
1-<2 10 (35.7) 9 (31.0) 7 (25.9) 12 (29.3)
2-<3 3 (10.7) 5 (17.2) 6 (22.2) 8 (19.5)
≥3 15 (53.6) 15 (51.7) 14 (51.9) 21 (51.2)
Abbreviations: BMI, bodymass index; IQR, interquartile range;
SD, standard deviation.
a All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
bRace/ethnicity data were self-reported by patients using fixed categories and
collected by qualified staff at each site per US Food and Drug Administration
regulations for sponsors of New Drug Applications.
c Bodymass index was calculated as weight in kilograms divided by height in
meters squared.
d Includes patients who used only plasma-derived C1 inhibitor.
e Incudes patients who used only oral therapy, which includes androgens
and antifibrinolytics.
f Patients using both C1 inhibitor and oral therapy for long-term prophylaxis.
g Month was defined as 28 days.
h The length of the run-in period was 4 weeks. Patients who experienced 3 or
more investigator-confirmed attacks before the end of the 4 weeks may have
exited the run-in period early and proceeded to enrollment and
randomization. Patients without 1 or more investigator-confirmed attack after
4 weeks of run-in may have extended their run-in for another 4 weeks, during
which time they needed to have 2 or more investigator-confirmed attacks to
proceed to enrollment and randomization. eTable 3 in Supplement 2
summarizes the duration of run-in for patients in each treatment group. Attack
rates were normalized to the number of attacks over 4 weeks. Because
patients may have had their run-in period shortened or extended, noninteger
values were possible.
i eTable 4 in Supplement 2 provides a more specific breakdown of the number
of patients by run-in attack rate category.
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group, and−1.77 (95%CI, −2.16 to−1.38) for the300-mgevery-
2-week group (Table 2 and Figure 2, A).
Prespecified Exploratory End Points
Over the 26-week treatment period, for patients in all 3 la-
nadelumab treatment groups, a significantly greater propor-
tion of patients were attack free (39.3% in the 150-mg every-
4-week group; P < .001; 31.0% in the 300-mg every-4-week
group;P = .001; and44.4%in the300-mgevery-2-weekgroup;
P < .001) compared with placebo (2.4%; Figure 2, B). There
were also significantlymore attack-free days permonth (26.9
inthe150-mgevery-4-weekgroup,P < .001;26.9 inthe300-mg
every-4-week group, P < .001; and 27.3 in the 300-mg every-
2-week group, P < .001) vs placebo (22.6; Table 3). Over the
26-week treatment period, 89.3% in the 150-mg every-4-
week group (P < .001) and 100% in both the 300-mg every-4-
week and 300-mg every-2-week groups (P < .001 for both)
treatedwith lanadelumab had a reduction in attack rate from
the run-in period of 50%ormore comparedwith 31.7% of pa-
tients in the placebo group. Reductions of 70% or more and
90% or more were observed in 75.9% to 88.9% and 55.2% to
66.7% of patients treated with lanadelumab (P < .001 for all)
comparedwith9.8%and4.9%ofpatients in theplacebogroup,
respectively (Table 3).
All attacks, including severity, duration, and use of on-
demand treatment, are depicted for each patient in Figure 3.
Primary attack location and attack duration are summarized
in eTable 5 and eTable 6 in Supplement 2, respectively. Over-
all, 20.2% of patients who received lanadelumab used intra-
venous C1-inhibitor on-demandmedication during the treat-
ment period compared with 65.9% of patients who received
placebo (see eTable 7 in Supplement 2). There was a signifi-
cant reduction in the rate of high-morbidity attacks following
lanadelumab treatment (mean difference vs placebo range,
−0.19 to −0.17 attacks per month; Table 3). The treatment ef-
fectwasconsistent inpatients regardlessofwhetherprior long-
termprophylaxiswasused, the run-inattack ratecategory, and
patient sex and bodymass index (eTable 8 in Supplement 2).
The results of the tipping-point analysis suggested that
missing data did not affect the findings; the postdiscontinu-
ation hereditary angioedema attack rate would have needed
to be 27, 22, and 35 times as high as observedduring the study
for the 3 lanadelumab treatment groups, respectively, to re-
verse the significance finding over placebo (eTable 9 in
Supplement2). The inclusionof geographical region in the sta-
tistical model also did not change the findings (P = .41 for
United States vs non-United States countries). The rate ratios
in this model were comparable with the ratios in the main
model (eTables 10 and 11 in Supplement 2).
Post Hoc Sensitivity Analysis
During the steady-state period (days 70-182), there was a
significant reduction in the monthly attack rate following
lanadelumab treatment: differencevsplacebowas−1.46 (95%
CI,−1.89 to−1.03 for the150-mgevery-4-weekgroup;P < .001),
−1.52 (95% CI, −1.93 to −1.11 for the 300-mg every-4-week
Figure 2. Primary and Secondary Efficacy End Points andMaximum Severity of Investigator-ConfirmedHereditary Angioedema Attacks
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All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
A, Attack rates are model-basedmean attacks per month, with a month defined
as 4 weeks. Themean attack rate for each group is presented with error bars
representing 95% CI.
B, Maximum hereditary angioedema attack severity is themost severe attack
reported by the patient. For patients who did not complete the study, all
available data were used for classification.
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group; P < .001), and −1.72 (95% CI, −2.12 to −1.33 for the
300-mg every-2-week group; P < .001; Table 4). The propor-
tion of patients with severe attacks alsowas lower in patients
treatedwith lanadelumab (3.6%[P = .02] in the 150-mgevery-
4-week group, 6.9% [P = .05] in the 300-mg every-4-week
group, and 3.8% [P = .02] in the 300-mgevery-4-week group)
comparedwithplacebo (27.0%).Furthermore, 1 patient (2.7%)
fromtheplacebogroupwas attack freeduring the steady state
periodcomparedwith 15patients (53.6%) in the 150-mgevery-
4-week group, 13 (44.8%) in the 300-mgevery-4-week group,
and 20 (76.9%) in the 300-mg every-2-week group (P < .001
for all lanadelumab groups vs placebo).
Quality of Life
Patients experienced a significant improvement in quality of
life total scores over 26weeks in all 3 lanadelumab treatment
groups comparedwith placebo (Table 4). A higher proportion
of patients treated with lanadelumab (65.4% in the 150-mg
every-4-week group, P = .047; 63.0% in the 300-mg every-4-
week group, P = .07; and 80.8% in the 300-mg every-2-week
group,P = .001) achieved theminimal clinically importantdif-
ference in total quality of life score20 compared with placebo
(36.8%). This corresponded to patients treated with lanadel-
umab having a significantly greater likelihood of achieving a
minimal clinically importantdifference (odds ratios, 3.2 in the
150-mgevery-4-week group,P = .03; 2.9 in the 300-mgevery
4 week group, P = .04; and 7.2 in the 300-mg every-2-week
group, P = .001) compared with placebo.
Adverse Events
The most commonly reported treatment-emergent adverse
events (excluding hereditary angioedema attacks) in patients
treated with lanadelumab during the entire treatment period
were injection site pain (42.9%), viral upper respiratory tract
infection (23.8%), headache (20.2%), injection site erythema
(9.5%), injection site bruising (7.1%), and dizziness (6.0%;
Table5).Most treatment-emergentadverseevents (98.5%)were
mild to moderate in severity. The most commonly reported
Table 2. Primary and Secondary Outcomes Among PatientsWith Hereditary Angioedema Attacks Taking Lanadelumab vs Placeboa
Lanadelumab
Placebo (n = 41)
Every 4 Weeks
300 mg Every 2 Weeks
(n = 27)150 mg (n = 28) 300 mg (n = 29)
Primary End Point
No. of attacks per mo, d 0-182
Mean (95% CI)b,c 0.48 (0.31 to 0.73) 0.53 (0.36 to 0.77) 0.26 (0.14 to 0.46) 1.97 (1.64 to 2.36)
Difference (95% CI)d −1.49 (−1.90 to −1.08) −1.44 (−1.84 to −1.04) −1.71 (−2.09 to −1.33)
P value <.001 <.001 <.001
Rate ratio (95% CI)c 0.24 (0.15 to 0.39) 0.27 (0.18 to 0.41) 0.13 (0.07 to 0.24)
P valuee <.001 <.001 <.001
Secondary End Points
No. of attacks requiring acute treatment
per mo, d 0-182
Mean (95% CI)b,c 0.31 (0.18 to 0.53) 0.42 (0.28 to 0.65) 0.21 (0.11 to 0.40) 1.64 (1.34 to 2.00)
Difference (95% CI)d −1.32 (−1.69 to −0.95) −1.21 (−1.58 to −0.85) −1.43 (−1.78 to −1.07)
P value <.001 <.001 <.001
Rate ratio (95% CI)c 0.19 (0.11 to 0.34) 0.26 (0.16 to 0.41) 0.13 (0.07 to 0.25)
P valuee <.001 <.001 <.001
No. of moderate or severe attacks
per mo, d 0-182
Mean (95% CI)b,c 0.36 (0.22 to 0.58) 0.32 (0.20 to 0.53) 0.20 (0.11 to 0.39) 1.22 (0.97 to 1.52)
Difference (95% CI)d −0.86 (−1.18 to −0.53) −0.89 (−1.20 to −0.58) −1.01 (−1.32 to −0.71)
P value <.001 <.001 <.001
Rate ratio (95% CI)c 0.30 (0.17 to 0.50) 0.27 (0.16 to 0.46) 0.17 (0.08 to 0.33)
P valuee <.001 <.001 <.001
No. of attacks per mo, d 14-182
Mean (95% CI)b,c 0.44 (0.28 to 0.70) 0.49 (0.33 to 0.73) 0.22 (0.12 to 0.41) 1.99 (1.65 to 2.39)
Difference (95% CI)d −1.54 (−1.96 to −1.12) −1.50 (−1.91 to −1.09) −1.77 (−2.16 to −1.38)
P value <.001 <.001 <.001
Rate ratio (95% CI)c 0.22 (0.14 to 0.36) 0.25 (0.16 to 0.38) 0.11 (0.06 to 0.21)
P valuee <.001 <.001 <.001
a All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
bAttack rates are model-basedmean attacks per month, defined as 4 weeks.
c Results are from a Poisson regressionmodel accounting for overdispersion;
treatment group and normalized baseline attack rate were fixed effects.
The logarithm of time (days) each patient was observed during the treatment
period was an offset variable. All P values (Wald test) reported vs placebo.
d Estimated from a nonlinear function of themodel parameters. All P values
(Wald test) reported vs placebo.
e P value adjusted for multiple testing.
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treatment-emergentadverseevents inpatients treatedwith la-
nadelumab thatwere considered related to treatmentwere in-
jection site pain (41.7%), injection site erythema (9.5%), injec-
tion site bruising (6.0%), and headache (7.1%). There were no
deaths or related serious treatment-emergent adverse events.
Two patients who received placebo withdrew from the
study due to treatment-emergent adverse events of tension
headache and hereditary angioedema attack, which were of
moderate severity. One patient in the lanadelumab 300-mg
every-4-weekgroupwithmetabolic syndrome, fatty liver, and
multiple concomitant suspect medications withdrew due to
isolated, asymptomatic, and transient elevation of alanine
transaminase (140 U/L) and aspartate transaminase (143 U/L)
classified as related and severe on day 139 (see eTable 12 in
Supplement 2; to convert aspartate and alanine transaminase
from U/L to μkat/L, multiply by 0.0167).
Clinical Laboratory Findings
During thescreeningandtreatmentperiods,allpatients (100%)
who received placebo and 83 of 84 patients (98.8%) in the
Table 3. Exploratory End Points Among PatientsWith Hereditary Angioedema Attacks Taking Lanadelumab vs Placeboa
Lanadelumab
Placebo (n = 41)
Every 4 Weeks
300 mg Every 2 Weeks
(n = 27)150 mg (n = 28) 300 mg (n = 29)
Responder analysis, No. (%)b
≥50% Reduction 25 (89.3) 29 (100) 27 (100) 13 (31.7)
Difference (95% CI) 57.6 (35.2 to 75.5) 68.3 (48.1 to 82.9) 68.3 (47.9 to 83.8)
P valuec <.001 <.001 <.001
≥70% Reduction 22 (78.6) 22 (75.9) 24 (88.9) 4 (9.8)
Difference (95% CI) 68.8 (48.0 to 84.1) 66.1 (45.2 to 82.1) 79.1 (60.0 to 91.6)
P valuec <.001 <.001 <.001
≥90% Reduction 18 (64.3) 16 (55.2) 18 (66.7) 2 (4.9)
Difference (95% CI) 59.4 (37.9 to 76.7) 50.3 (27.7 to 68.8) 61.8 (39.5 to 78.8)
P valuec <.001 <.001 <.001
Maximum attack severity, No. (%)
Attack free 11 (39.3) 9 (31.0) 12 (44.4) 1 (2.4)
Difference (95% CI) 36.8 (13.1 to 57.5) 28.6 (5.0 to 50.0) 42.0 (18.1 to 61.8)
P valuec <.001 .001 <.001
Mild 2 (7.1) 6 (20.7) 3 (11.1) 1 (2.4)
Difference (95% CI) 4.7 (−19.3 to 27.9) 18.3 (−5.4 to 40.6) 8.7 (−15.6 to 32.0)
P valuec .56 .02 .29
Moderate 10 (35.7) 10 (34.5) 10 (37.0) 25 (61.0)
Difference (95% CI) −25.3 (−47.2 to −0.9) −26.5 (−48.2 to −2.5) −23.9 (−46.7 to 0.7)
P valuec .05 .05 .08
Severe 5 (17.9) 4 (13.8) 2 (7.4) 14 (34.1)
Difference (95% CI) −16.3 (−39.1 to 7.8) −20.4 (−42.5 to 3.5) −26.7 (−48.9 to −2.8)
P valuec .18 .09 .02
Attack-free d per mo, mean (SD), d 26.9 (1.6) 26.9 (1.3) 27.3 (1.3) 22.6 (4.4)
Difference (95% CI) 4.3 (2.7 to 5.8) 4.3 (2.8 to 5.8) 4.7 (3.2 to 6.2)
P valued <.001 <.001 <.001
No. high-morbidity attacks per mo
Mean (95% CI)e,f 0.05 (0.01 to 0.15) 0.03 (0.01 to 0.12) 0.03 (0.01 to 0.13) 0.22 (0.14 to 0.35)
Difference (95% CI)g −0.17 (−0.29 to −0.06) −0.19 (−0.30 to −0.08) −0.19 (−0.30 to −0.07)
P value .004 <.001 .001
Rate ratio (95% CI)f 0.21 (0.06 to 0.75) 0.14 (0.03 to 0.58) 0.15 (0.04 to 0.65)
P value .02 .007 .01
a P values shown for exploratory end points were not adjusted for multiplicity.
All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
bAchievement of a prespecified reduction from the run-in period in the
hereditary angioedema attack rate. The percentage reduction was calculated
as the run-in period attack rate minus the treatment period attack rate divided
by the run-in period attack rate, multiplied by 100.
c The difference vs placebo was analyzed using Fisher exact test.
d The difference vs placebo was analyzed using a t test.
e Attack rates are model-basedmean attacks per month, defined as 4 weeks.
f Results are from a Poisson regressionmodel accounting for overdispersion;
treatment group and the normalized baseline attack rate were fixed effects.
The logarithm of time (days) each patient was observed during the treatment
period was an offset variable. All P values (Wald test) reported vs placebo.
g Estimated from a nonlinear function of themodel parameters. All P values
(Wald test) reported vs placebo.
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pooled lanadelumab treatment groupshadvalues 1.5 times or
less than theupper limit of normal for activatedpartial throm-
boplastin time.Thevalue increased tomore than 1.5 times the
upper limit ofnormal for 1patient (1.2%)whoreceived300-mg
every 2 weeks (eTables 14, 15, and 16 in Supplement 2).
Hypersensitivity Reactions
Onepatient in the 300-mgevery-2-week group reported 2hy-
persensitivity reactionswith symptomsofmouth tingling and
pruritus, which were of mild and moderate intensity, tran-
sient, and recoveredwithoutneed for treatmentor futurepre-
medication. The patient continued into the open-label
extension. No laboratory abnormalities or presence of anti-
drug antibodies were observed in this patient to date.
Antidrug Antibodies
Ten of 84 patients (11.9%) in the lanadelumab group and 2 of
41 patients (4.9%) in the placebo group tested positive for
low-titer (range, 20-1280) treatment-emergent antidrug anti-
bodies, which were transient in 2 of 10 patients treated with
lanadelumaband 1of 2patients treatedwithplacebo.Lowpre-
existing antibody titers were observed in 3 patients in the
lanadelumab group and 1 in the placebo group with antidrug
antibodypositivity.Neutralizingantibodiesweredetectednear
Figure 3. Overview of Investigator-ConfirmedHereditary Angioedema Attacks and Use of On-DemandMedication
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Each horizontal line represents data for an individual patient. Profiles are
presented in order by the attack rate during the run-in period. The width of the
blue boxes indicates the duration of the attack and the height indicates the
severity of the attack. Orange circles indicate the use of on-demandmedication.
The dotted line at day 70 represents the start of steady state (days 70-182).
The solid line represents end of the run-in period. All patients received
injections every 2 weeks, with those in the every-4-week groups receiving
placebo in between active treatments.
a Discontinued the study and did not complete the treatment period.
bDiscontinued the study but completed the treatment period. See eTable 2 in
Supplement 2 for a summary of treatment duration for patients who did not
complete the study and reasons for discontinuation.
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Table 4. Post Hoc End Points and Health–Related Quality of Life Among PatientsWith Hereditary Angioedema Attacks
Taking Lanadelumab vs Placeboa
Lanadelumab
Placebo (n = 41)
Every 4 Weeks
300 mg Every 2 Weeks (n = 27)150 mg (n = 28) 300 mg (n = 29)
Post hoc End Pointsb
Attacks per mo
during steady statec
No. of Patients 28 29 26 37
Mean (95% CI)d,e 0.42 (0.26 to 0.68) 0.37 (0.22 to 0.60) 0.16 (0.07 to 0.35) 1.88 (1.54 to 2.30)
Difference (95% CI)f −1.46 (−1.89 to −1.03) −1.52 (−1.93 to −1.11) −1.72 (−2.12 to −1.33)
P value <.001 <.001 <.001
Rate ratio (95% CI)e 0.22 (0.13 to 0.38) 0.19 (0.12 to 0.33) 0.09 (0.04 to 0.19)
P value <.001 <.001 <.001
Maximum attack severity
during steady state,
No. (%)c
Attack free 15 (53.6) 13 (44.8) 20 (76.9) 1 (2.7)
Difference (95% CI) 50.9 (28.0 to 69.9) 42.1 (18.6 to 62.2) 74.2 (53.6 to 88.6)
P valueg <.001 <.001 <.001
Mild 3 (10.7) 4 (13.8) 2 (7.7) 2 (5.4)
Difference (95% CI) 5.3 (−19.0 to 29.3) 8.4 (−16.0 to 31.7) 2.3 (−22.6 to 26.9)
P valueg .64 .39 >.99
Moderate 9 (32.1) 10 (34.5) 3 (11.5) 24 (64.9)
Difference (95% CI) −32.7 (−54.3 to −8.0) −30.4 (−52.2 to −5.9) −53.3 (−72.1 to −29.8)
P valueg .01 .03 <.001
Severe 1 (3.6) 2 (6.9) 1 (3.8) 10 (27.0)
Difference (95% CI) −23.5 (−45.9 to 1.2) −20.1 (−42.9 to 4.2) −23.2 (−46.3 to 2.1)
P valueg .02 .05 .02
Health–Related Quality of Life
No. of patients 26 27 26 38
Change in total score,
from d 0-182,
mean (95% CI)h
–19.82 (−26.76 to −12.88) –17.38 (−24.17 to −10.58) –21.29 (−28.21 to −14.37) –4.72 (−10.46 to 1.02)
P valuei
Change vs placebo,
mean (95% CI)
−15.11 (−27.12 to −3.09) −12.66 (−24.51 to −0.80) −16.57 (−28.53 to −4.62)
P valuej .008 .03 .003
Responded to therapy, %k 65.38 62.96 80.77 36.84
P value .047 .07 .001
Odds ratio (95% CI) 3.24 (1.14 to 9.19) 2.91 (1.05 to 8.10) 7.20 (2.22 to 23.37)
P value .03 .04 .001
a All patients received injections every 2 weeks, with those in the every-4-week
groups receiving placebo in between active treatments.
bP values shown for exploratory end points were not adjusted for multiplicity.
c The 16-week steady state period included days 70 through 182.
dAttack rates are model-basedmean attacks per month, with a month defined
as 4 weeks.
e Results are from a Poisson regressionmodel accounting for overdispersion;
treatment group and normalized baseline attack rate were fixed effects.
The logarithm of time (days) each patient was observed during the
treatment period was an offset variable. All P values (Wald test) reported
vs placebo.
f Estimated from a nonlinear function of themodel parameters. All P values
(Wald test) reported vs placebo.
g The difference vs placebo was analyzed using Fisher exact test.
h Change in Angioedema Quality of Life scores are controlled for baseline scores
and are least square means.
i This is a single P value <.001 for the analysis of covariance test, which shows
the difference among the 4 groups.
j Analysis of covariance post hoc pairwise comparison (Tukey-Kramer)
vs placebo.
k Patients who were considered to have responded (responders) to the therapy
were defined as achieving an improvement greater than or equal to the
minimal clinically important difference of –6 for total scores from days 0
through 182. The questionnaire consisted of 4 domains (functioning, fatigue
andmood, fears and shame, and nutrition) and 17 questions that were taken
together for a total score. Total raw scores were transformed to a linear scale
of 0 to 100, with lower scores indicating lower impairment or higher
health–related quality of life.20 Odds ratios represent times the odds (vs not)
to achieve a responder definition compared with placebo.
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the end of the treatment period in 2 patients who received
150-mg of lanadelumab every 4 weeks; 1 was transient (see
eTables 17 and 18 in Supplement 2).
Discussion
In this study, all 3 lanadelumab treatment regimens pro-
duced statistically significant reductions in themean heredi-
tary angioedema attack rate compared with placebo for the
number of attacks from days 0 to 182, the number of attacks
requiring acute treatment, and thenumber ofmoderate or se-
vere attacks, as well as the number of attacks from days 14
through 182.
In addition to a reduction in the overall hereditary angio-
edemaattack rate, reductions in thenumber of attacks requir-
ing acute treatment or that were moderate or severe reflects
the full treatment effect of lanadelumab in reducing the bur-
den of individual breakthrough hereditary angioedema at-
tacks.Thenumberof attacksand thechange inattack ratewith
lanadelumab treatment vs placebo from days 14 through 182
was similar to those from days 0 through 182, indicating an
early onset of the treatment effect of lanadelumab.
Even with 56% of patients receiving prior long-term pro-
phylaxis, 52%experiencing 3 ormorehereditary angioedema
attacks during the run-in period, and 64.8% with a history
of laryngeal attacks, a total of 38.1% of patients treated with
lanadelumabwereattack freeover theentire treatmentperiod.
Furthermore, estimatesof treatmenteffect for theprimaryand
secondary efficacy analyses were assessed by including all
hereditary angioedemaattacks after the first doseof the study
drug, despite time to steady state concentrations for lanadel-
umab being approximately 70 days.14 In a post hoc analysis
looking only at the effect of lanadelumab during the steady-
state period, the reduction in attack rates raises the possibil-
ity that there could be further improvement in controlling
hereditary angioedema once steady-state concentrations
are achieved.
A significant improvement in patient-reported health–
related quality of life was demonstrated in the study. The ex-
tent of improvement inquality of life total scoreswith lanadel-
umab compared with placebo was similar to that seen with
omalizumabcomparedwithplaceboforthetreatmentofchronic
spontaneousurticaria inpatientswith recurrent angioedema21
andwas greater than that seenwith subcutaneous C1 inhibitor
with recombinant hyaluronidase for prophylaxis,22 although
treatment duration differed in these trials.
Themajority (93.3%)of treatment-emergentadverseevents
related to lanadelumab were associated with the injection
site. The higher incidence of related treatment-emergent ad-
verseeventsamongpatients treatedwith lanadelumabwaspre-
dominantly due to injection site pain (reported by 41.7% of
lanadelumab-treated patients vs 26.8% who received pla-
cebo), contrasting with previous findings in which the inci-
dence of injection site pain was comparable between patients
treated with lanadelumab and placebo.14 Overall, the rates of
injection site painmay have been associatedwith the require-
ment for thestudydrug tobeadministeredas2separate 1.0-mL
injections intheupperarmtomaintainblinding.Additionalclar-
ity may be gained from the ongoing open-label extension,
Table 5. Adverse Eventsa
Adverse Eventsb
No. (%) of Patients
Lanadelumab
Placebo
(n = 41)
Every 4 Weeks 300 mg
Every 2 Weeks
(n = 27)
Total
(n = 84)
150 mg
(n = 28)
300 mg
(n = 29)
Any adverse event 25 (89.3) 25 (86.2) 26 (96.3) 76 (90.5) 31 (75.6)
Injection site pain 13 (46.4) 9 (31.0) 14 (51.9) 36 (42.9) 12 (29.3)
Viral upper respiratory
tract infection
3 (10.7) 7 (24.1) 10 (37.0) 20 (23.8) 11 (26.8)
Headache 3 (10.7) 5 (17.2) 9 (33.3) 17 (20.2) 8 (19.5)
Injection site
Erythema 4 (14.3) 2 (6.9) 2 (7.4) 8 (9.5) 1 (2.4)
Bruising 3 (10.7) 2 (6.9) 1 (3.7) 6 (7.1) 0
Dizziness 1 (3.6) 3 (10.3) 1 (3.7) 5 (6.0) 0
Any treatment-related
adverse eventc
17 (60.7) 14 (48.3) 19 (70.4) 50 (59.5) 14 (34.1)
Injection site
Pain 12 (42.9) 9 (31.0) 14 (51.9) 35 (41.7) 11 (26.8)
Erythema 4 (14.3) 2 (6.9) 2 (7.4) 8 (9.5) 1 (2.4)
Bruising 2 (7.1) 2 (6.9) 1 (3.7) 5 (6.0) 0
Headache 1 (3.6) 2 (6.9) 3 (11.1) 6 (7.1) 1 (2.4)
Any serious adverse eventd 0 3 (10.3) 1 (3.7) 4 (4.8) 0
Any related serious
adverse event
0 0 0 0 0
Any adverse event
leading to discontinuation
0 1 (3.4) 0 1 (1.2) 1 (2.4)e
a All patients received injections
every 2 weeks, with those in the
every-4-week groups receiving
placebo in between active
treatments.
b Treatment-emergent adverse
events that were reported at the
Preferred Term level in 5% or more
of patients in the total
lanadelumab-treated group and
excludes hereditary angioedema
attack–reported events. Adverse
events were collected over the
entire treatment period and were
assigned to the treatment group
without regard to the type of
injection (ie, placebo or active drug
in the 150-mg every-4-week and
300-mg every-4-week groups).
c Adverse events that were judged by
the investigator to be related to the
use of the investigational product.
d See eTable 13 in Supplement 2 for
details on serious adverse events.
e One patient withdrew due to a
hereditary angioedema attack and is
not included. See eTable 12 in
Supplement 2 for details on adverse
events leading to discontinuation.
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duringwhichpatients are able to self-administer a single injec-
tionata siteof their choosing (abdomen, thigh,orupperarm).17
Antidrug antibodies of low titer developed in 11.9% of pa-
tients treated with lanadelumab and 4.9% of patients treated
with placebo. As a monoclonal antibody, lanadelumab is con-
sidered to have a lower risk of off-target effects due to its high
selectivity and specificity; however, the possibility of an im-
muneresponsetothis fullyhumanmonoclonalantibodyshould
beconsidered.Twopatients treatedwith lanadelumab 150-mg
every 4weeks developed antibodies that showed neutralizing
properties in vitro. There are other potential antigenic sites on
lanadelumab and not all would interfere with the binding of
plasma kallikrein. Thus, it would be possible that nonneutral-
izing antidrug antibodies are directed to epitopes on lanade-
lumab other than those engaged in binding plasma kallikrein.
The identificationofantidrugantibodies to lanadelumab inpa-
tients treated with placebo is likely attributed to the high sen-
sitivity of the assay and the potential for false-positive results.
This study had an observation period of 26weeks of treat-
ment; therefore, itwasnotpossible toassess theadverseevents
andpreventiveeffectsofcontinuousprophylaxiswithlong-term
plasma kallikrein inhibition. Data from the ongoing open-label
extension17will provide additional insights into these areas. Of
note, inpatientswithseverecongenitaldeficiencyofprekallikrein
(Fletcher factordeficiency), themain laboratory finding isapro-
longed activated partial thromboplastin time.23 In the current
study, all but 1patient treatedwith lanadelumabmaintainedan
activated partial thromboplastin time of less than 1.5 times the
upper limit of normal throughout the treatment period.
Limitations
This study had several limitations. First, there were relatively
fewpatients in each treatment group,which led to imbalances
in some baseline demographic and clinical characteristics.
Second, this studywas limited to26weeks.Althoughmost
patientswould likely continue therapywith lanadelumabover
a longperiod,conclusionson long-termsafetyandefficacycan-
not be made.
Third, the reportednumberof attacks in the 12monthsbe-
fore screeningwere based onpatient historical recall, and the
attacks were not investigator confirmed. Thus, these data
should be interpreted with caution.
Conclusions
Amongpatientswithhereditary angioedema type I or II, treat-
ment with subcutaneous lanadelumab for 26 weeks signifi-
cantly reduced the number of attacks compared with pla-
cebo, supporting the use of lanadelumab as a prophylactic
therapy forhereditaryangioedema.Further research isneeded
to determine long-term safety and efficacy.
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